Tryptophol and 4-Ethyl-Phenol Compositions for Bidirectional Coagulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compositions and methods to effectively modulate blood coagulation in subjects with either excessive or deficient clotting, such as in conditions like hemophilia or diabetes, to prevent uncontrolled bleeding or thrombosis.
Innovation Solution
A composition comprising a Tryptophol derivative and a 4-Ethyl-Phenol derivative, such as Tryptophol acetate and Tyrosol acetate, is administered to modulate blood coagulation by either accelerating or decelerating clotting processes, depending on the subject's need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a single coagulation treatment is administered, then blood coagulation is improved in subjects with bleeding issues, but it may cause harmful effects in subjects prone to thrombosis
Solution Approach 1:
The patent employs a dynamic dosing strategy where the amount of coagulation treatment administered varies based on the subject's real-time coagulation status. The system continuously monitors coagulation parameters and adjusts the treatment dose accordingly - administering higher doses to subjects with bleeding issues while reducing or withholding doses from subjects showing signs of thrombosis risk, thereby adapting the treatment to individual physiological needs
Solution Approach 2:
The patent implements a feedback mechanism where coagulation parameters are continuously measured and used to adjust subsequent treatment decisions. The system monitors clotting time, fibrinogen levels, and other coagulation markers, then uses this information to modulate the coagulation treatment dosage, creating a closed-loop control system that prevents both under-treatment and over-treatment
2Reliability
If coagulation factors are administered to normalize abnormal coagulation, then bleeding is controlled, but the treatment complexity and time required increase
Solution Approach 1:
The patent employs preliminary action by pre-formulating coagulation treatments with optimized compositions and dosages based on predicted patient needs. The system prepares treatment regimens in advance that can be quickly administered when bleeding occurs, and pre-identifies patients who may need prophylactic treatment, thereby reducing the response time when coagulation intervention is required
Solution Approach 2:
The patent utilizes parameter changes by modifying coagulation treatment formulations to achieve faster onset of action. This includes adjusting the concentration of coagulation factors, using modified formulations with improved bioavailability, and optimizing administration routes to achieve rapid therapeutic effects, thereby normalizing coagulation more quickly
3Object-affected harmful factors
If anticoagulant therapy is administered to prevent thrombosis, then clot formation is reduced, but bleeding risk increases
Solution Approach 1:
The patent applies dynamic adjustment to anticoagulant therapy by continuously monitoring patients' coagulation status and adjusting the anticoagulant dosage in real-time. The system reduces anticoagulant doses when bleeding risk is detected and increases doses when thrombosis risk is high, thereby dynamically balancing thrombosis prevention with bleeding risk management based on individual patient physiology
Data Source
AI summary
The present invention is directed to a composition including a Tryptophol derivative, a 4-Ethyl-Phenol derivative, or a combination thereof, and a method of using same, such as for treating a subject in need of modulation of blood coagulation.